|
|
| (186 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | + | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32371564|t=2020. Clinical presentation and course of COVID-19 |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32366502|t=2020. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies |pdf=|usr=}}
| + | |
| − | {{tp|p=32252141|t=2020. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32252139|t=2020. Epidemiology and clinical features of coronavirus disease 2019 in children |pdf=|usr=}}
| + | |
| − | {{tp|p=32207680|t=2020. COVID-19: the new challenge for rheumatologists |pdf=|usr=}}
| + | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32197957|t=ä. What Should Gastroenterologists and Patients Know About COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32276137|t=ä. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic |pdf=|usr=}}
| + | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32325252|t=2020. COVID-19 pathophysiology: A review |pdf=|usr=}}
| + | |
| | + | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | *
| |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32311462|t=2020. On the molecular determinants of the SARS-CoV-2 attack |pdf=|usr=}}
| |
| − | {{tp|p=32129843|t=ä. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients |pdf=|usr=}}
| |
| − | {{tp|p=32129842|t=ä. A glimpse into the origins of genetic diversity in SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Target binding and uptake]]'''
| |
| − | {{tp|p=32220422|t=2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Target binding and uptake]]''' |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | + | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32339487|t=2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China |pdf=|usr=}}
| |
| − | {{tp|p=32333860|t=2020. Presepsin in risk stratification of SARS-CoV-2 patients |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32145275|t=2020. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32348783|t=2020. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis |pdf=|usr=}}
| |
| − | {{tp|p=32202240|t=2020. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?|pdf=|usr=}}
| |
| | | | |
| − | *'''[[Microvascular]]''' | + | |
| − | * | + | |
| | + | *'''[[Pathobiology]]''' |
| | + | |
| | + | |
| | + | *'''[[Disease Models]]''' |
| | + | |
| | + | |
| | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | *'''[[Early symptoms]]''' | | *'''[[Early symptoms]]''' |
| | + | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32358954|t=ä. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing |pdf=|usr=}}
| |
| − | {{tp|p=32361747|t=ä. COVID-19, superinfections and antimicrobial development: What can we expect?|pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| − | {{tp|p=32173725|t=ä. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China |pdf=|usr=}}
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32250159|t=2020. Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients |pdf=|usr=}}
| + | |
| | + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32178975|t=ä. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32371557|t=2020. SARS-CoV-2 and myocardial injury: Few answers, many questions |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32357210|t=ä. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32215618|t=ä. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| − | {{tp|p=32371556|t=2020. Hyperglycemia management in the critically ill patient with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32205220|t=ä. Don t Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32278065|t=ä. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management |pdf=|usr=}}
| |
| − | {{tp|p=32334083|t=ä. Current Knowledge and Research Priorities in the Digestive Manifestations of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32311512|t=ä. Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32283325|t=ä. Clinical Features of COVID-19-Related Liver Damage |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Kidney, urology]]==
| |
| − | *
| |
| − | *'''[[Pathobiology]]'''
| |
| − | {{tp|p=32334082|t=ä. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Disease Models]]''' | + | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32215622|t=ä. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]''' | + | *'''[[Kidney, urology]]''' |
| − | *
| + | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| + | |
| − | {{tp|p=32360478|t=2020. Emerging key laboratory tests for patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32077933|t=ä. ...Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32154877|t=ä. The SARS-CoV-2 Outbreak: Diagnosis, Infection Prevention, and Public Perception |pdf=|usr=}}
| + | |
| − | {{tp|p=32246822|t=ä. Potential false-negative nucleic acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation of samples with low viral loads |pdf=|usr=}}
| + | |
| − | {{tp|p=32353116|t=ä. Modeling SARS-CoV-2 positivity using laboratory data: timing is everything |pdf=|usr=}}
| + | |
| − | {{tp|p=32343775|t=ä. SARS-CoV-2 Serology: Much Hype, Little Data |pdf=|usr=}}
| + | |
| − | {{tp|p=32315390|t=ä. Rapid detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform |pdf=|usr=}}
| + | |
| − | {{tp|p=32282874|t=ä. Limits of Detection of Six Approved RT?PCR Kits for the Novel SARS-coronavirus-2 (SARS-CoV-2) |pdf=|usr=}}
| + | |
| − | {{tp|p=32031590|t=ä. Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV) |pdf=|usr=}}
| + | |
| − | {{tp|p=32229107|t=2020. Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient |pdf=|usr=}}
| + | |
| − | {{tp|p=32031583|t=ä. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32156607|t=ä. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32343948|t=2020. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study |pdf=|usr=}}
| + | |
| − | {{tp|p=32335089|t=ä. Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories |pdf=|usr=}}
| + | |
| − | {{tp|p=32315614|t=2020. Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32295319|t=2020. Innovative screening tests for COVID-19 in South Korea |pdf=|usr=}}
| + | |
| − | {{tp|p=32358960|t=ä. Evaluation of COVID-19 RT-qPCR test in multi-sample pools |pdf=|usr=}}
| + | |
| − | {{tp|p=32357209|t=ä. Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32357206|t=ä. Role of serology in the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32221523|t=ä. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32221519|t=ä. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]''' | + | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32120312|t=2020. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: The value of CT images in the course of the disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32302927|t=2020. Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review |pdf=|usr=}}
| + | |
| − | {{tp|p=32361535|t=ä. COVID-19 pneumonia patient without clear epidemiological history outside Wuhan: An analysis of the radiographic and clinical features |pdf=|usr=}}
| + | |
| − | {{tp|p=32361413|t=2020. Initial CT imaging characters of an imported family cluster of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32358955|t=ä. Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection |pdf=|usr=}}
| + | |
| − | {{tp|p=32232429|t=ä. Computed Tomographic Imaging of 3 Patients With Coronavirus Disease 2019 Pneumonia With Negative Virus Real-time Reverse-Transcription Polymerase Chain Reaction Test |pdf=|usr=}}
| + | |
| − | {{tp|p=32227091|t=ä. Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section CT Features During Recovery |pdf=|usr=}}
| + | |
| − | {{tp|p=32198501|t=ä. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32283324|t=ä. COVID-19 ? Considerations for the paediatric rheumatologist |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Respiration mgmt]]''' | + | *'''[[Case reports]]''' |
| − | {{tp|p=32371555|t=2020. Utility of extracorporeal membrane oxygenation in COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32371563|t=2020. Asthma increases risk of severity of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32360479|t=ä. 2019 novel coronavirus disease (COVID-19) in hemodialysis patients: a report of two cases |pdf=|usr=}}
| |
| − | {{tp|p=32360811|t=ä. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts |pdf=|usr=}}
| |
| − | {{tp|p=32334081|t=ä. HEALTH STATUS OF LIVER TRANSPLANTED PATIENTS DURING THE CORONAVIRUS OUTBREAK IN ITALY: A LARGE SINGLE CENTER EXPERIENCE FROM MILAN |pdf=|usr=}}
| |
| − | {{tp|p=32276139|t=2020. COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster |pdf=|usr=}}
| |
| − | {{tp|p=32276140|t=2020. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients |pdf=|usr=}}
| |
| − | {{tp|p=32249918|t=ä. Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study |pdf=|usr=}}
| |
| − | {{tp|p=32215613|t=ä. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System?a Call for Epidemiologic Investigations |pdf=|usr=}}
| |
| − | {{tp|p=32182347|t=ä. Perinatal Transmissionof COVID-19 Associated SARS-CoV-2:Should We Worry?|pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32147731|t=ä. Diagnosis and Management of First Case of COVID-19 in Canada: Lessons applied from SARS |pdf=|usr=}}
| |
| − | {{tp|p=32227197|t=ä. A Community Transmitted Case of Severe Acute Respiratory Distress Syndrome due to SARS CoV2 in the United States |pdf=|usr=}}
| |
| − | {{tp|p=32211789|t=ä. The first locally acquired novel case of 2019-nCoV infection in a healthcare worker in the Paris area |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32308494|t=2020. Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China |pdf=|usr=}}
| |
| − | {{tp|p=32361723|t=ä. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32361738|t=ä. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32232322|t=ä. Disparities in Age-Specific Morbidity and Mortality from SARS-CoV-2 in China and the Republic of Korea |pdf=|usr=}}
| |
| − | {{tp|p=32211844|t=ä. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32179890|t=ä. Risk Factors of Healthcare Workers with Corona Virus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | + | *'''[[Registries]]''' |
| | | | |
| − | {{tp|p=32176772|t=ä. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China |pdf=|usr=}}
| |
| | | | |
| − | *
| |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| | + | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32371558|t=2020. Hydroxychloroquine use in the COVID-19 patient |pdf=|usr=}}
| |
| − | {{tp|p=32272008|t=2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32337664|t=ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32359035|t=2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}}
| |
| − | {{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}}
| |
| − | {{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}
| |
| − | {{tp|p=32353634|t=2020. COVID-19: Immunology and treatment options |pdf=|usr=}}
| |
| − | {{tp|p=32335290|t=2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32150618|t=ä. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32211771|t=ä. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?|pdf=|usr=}}
| |
| − | {{tp|p=32211764|t=ä. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| − | {{tp|p=32311512|t=ä. Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − | *'''[[The morbid survivor]]'''
| |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | *'''[[Other routes of infection]]'''
| + | |
| | + | |
| | + | |
| | + | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | *
| + | |
| | + | |
| | + | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32371561|t=2020. Pulmonary function testing precautions in a time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32371560|t=2020. PAP therapy increases the risk of transmission of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32252508|t=2020. Sharing Our Experience of Operating an Endoscopy Unit in the Midst of a COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32371164|t=ä. RECOMMENDATIONS FOR ESSENTIAL ESOPHAGEAL PHYSIOLOGICTESTING DURING THE COVID-19 PANDEMIC |pdf=|usr=}}
| |
| − | {{tp|p=32304737|t=ä. Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| | + | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32371559|t=2020. Helping children cope with the COVID-19 pandemic |pdf=|usr=}}
| + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Educational aspects of the status hygienicus]]''' | | *'''[[Educational aspects of the status hygienicus]]''' |
| − | *
| + | ---- |
| | + | |
| | + | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| | + | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | + | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32227121|t=ä. The Late Arrival of COVID-19 in Africa - Mitigating Pan-Continental Spread |pdf=|usr=}}
| |
| − | {{tp|p=32201889|t=ä. COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]''' | + | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | + | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | + | |
| | + | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| | + | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | + | ---- |
| | + | |
| | + | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | *'''[[Current state of coviki.org]]'''
| |
| − | *[[PubMed selected papers unsorted to be listed in contents topics]]
| |
| − | *[[coviki state of development]]
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| | + | |
| | + | |
| | + | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | + | *'''[[from the ads]]''' |
| | + | |
| | + | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
